Literature DB >> 2858733

Regression of metastatic vipoma with somatostatin analogue SMS 201-995.

D Clements, E Elias.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858733     DOI: 10.1016/s0140-6736(85)92235-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  20 in total

Review 1.  Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.

Authors:  Wouter W de Herder; Steven W J Lamberts
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 2.  Therapeutic potential of a long acting somatostatin analogue in gastrointestinal diseases.

Authors:  L J O'Donnell; M J Farthing
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

3.  The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel.

Authors:  A Bianchi; L De Marinis; A Fusco; F Lugli; L Tartaglione; D Milardi; M Mormando; A P Lassandro; R Paragliola; C A Rota; S Della Casa; S M Corsello; M G Brizi; A Pontecorvi
Journal:  J Endocrinol Invest       Date:  2011-11-07       Impact factor: 4.256

4.  Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors.

Authors:  Thomas E Clancy; Tanya P Sengupta; Jessica Paulus; Fawzia Ahmed; Mei-Sheng Duh; Matthew H Kulke
Journal:  Dig Dis Sci       Date:  2006-06-07       Impact factor: 3.199

5.  Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report.

Authors:  C C Case; K Wirfel; R Vassilopoulou-Sellin
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

6.  Four year treatment with a long acting somatostatin analogue in a patient with Verner-Morrison syndrome.

Authors:  A Brunani; C Crespi; M De Martin; A Dubini; M Piolini; F Cavagnini
Journal:  J Endocrinol Invest       Date:  1991-09       Impact factor: 4.256

Review 7.  Antitumor effects of somatostatin analogs in neuroendocrine tumors.

Authors:  Lucas Sidéris; Pierre Dubé; Anja Rinke
Journal:  Oncologist       Date:  2012-05-24

8.  Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995.

Authors:  B Wiedenmann; U Räth; R Rädsch; F Becker; B Kommerell
Journal:  Klin Wochenschr       Date:  1988-01-15

9.  Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors.

Authors:  D Gomez; H Z Malik; A Al-Mukthar; K V Menon; G J Toogood; J P A Lodge; K R Prasad
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

10.  Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.

Authors:  R Arnold; C Neuhaus; R Benning; W B Schwerk; M E Trautmann; K Joseph; C Bruns
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.